Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
NTRA [NASD]
Natera, Inc.
Healthcare | Diagnostics & Research | USA
statements
Index- P/E- EPS (ttm)-3.10 Insider Own1.60% Shs Outstand86.69M Perf Week6.53%
Market Cap9.28B Forward P/E- EPS next Y-3.51 Insider Trans-27.24% Shs Float84.52M Perf Month19.18%
Income-258.20M PEG- EPS next Q-1.07 Inst Own99.77% Short Float7.94% Perf Quarter-0.15%
Sales449.30M P/S20.66 EPS this Y-58.00% Inst Trans2.27% Short Ratio7.63 Perf Half Y9.94%
Book/sh4.30 P/B24.16 EPS next Y10.00% ROA-29.30% Target Price133.50 Perf Year162.85%
Cash/sh7.31 P/C14.21 EPS next 5Y- ROE-60.80% 52W Range39.43 - 127.19 Perf YTD4.38%
Dividend- P/FCF- EPS past 5Y-15.20% ROI-30.10% 52W High-18.33% Beta1.29
Dividend %- Quick Ratio4.60 Sales past 5Y15.50% Gross Margin49.80% 52W Low163.43% ATR4.82
Employees1815 Current Ratio4.70 Sales Q/Q62.00% Oper. Margin-55.70% RSI (14)59.79 Volatility4.15% 4.51%
OptionableYes Debt/Eq0.89 EPS Q/Q-63.00% Profit Margin-57.50% Rel Volume0.53 Prev Close103.88
ShortableYes LT Debt/Eq0.75 EarningsMay 06 AMC Payout- Avg Volume878.88K Price103.87
Recom1.60 SMA2010.07% SMA503.54% SMA20011.38% Volume74,749 Change-0.01%
May-25-21Initiated Wells Fargo Overweight $110
Jan-28-21Initiated Truist Buy $143
Oct-08-20Initiated BTIG Research Buy $90
Sep-28-20Initiated Morgan Stanley Overweight $80
Sep-17-20Initiated SVB Leerink Outperform $75
Jun-10-20Resumed Piper Sandler Overweight $56 → $63
May-07-20Upgrade JP Morgan Neutral → Overweight $32 → $45
Oct-05-18Initiated JP Morgan Neutral $26
Jul-05-18Reiterated Piper Jaffray Overweight $18 → $21
Aug-07-17Reiterated Morgan Stanley Overweight $18 → $13
Nov-10-16Reiterated The Benchmark Company Buy $16 → $20
May-23-16Reiterated The Benchmark Company Buy $15 → $16
May-11-16Reiterated The Benchmark Company Buy $14 → $15
Apr-19-16Initiated The Benchmark Company Buy $14
Sep-28-15Upgrade Wedbush Neutral → Outperform
Aug-14-15Upgrade Morgan Stanley Equal-Weight → Overweight
Aug-04-15Initiated Robert W. Baird Outperform $20
Jul-27-15Initiated Wedbush Neutral $20
Jul-27-15Initiated Piper Jaffray Overweight $24
Jul-27-15Initiated Morgan Stanley Equal-Weight $20
Jun-08-21 07:03AM  
Foundation Medicine Launches FoundationOne®Tracker ctDNA Monitoring Assay for Research Use in Partnership with Natera
PR Newswire
Jun-04-21 09:03AM  
Natera Announces New Prospera Data at the ATC 2021 Virtual Connect Conference
PR Newswire
May-28-21 04:52PM  
Natera Responds to Meritless Lawsuit and Files False Advertising Claim Against Guardant for Misleading Oncologists
PR Newswire
May-26-21 09:03AM  
New Signatera Data in Multiple Myeloma, Colorectal Cancer and Ovarian Cancer Highlights Clinical Utility of MRD in Real-World Settings
PR Newswire
May-20-21 09:03AM  
Natera to Present Clinical Data from Largest Prospective MRD-Guided Trial in Colorectal Cancer at the 2021 ASCO Annual Meeting
PR Newswire
May-10-21 02:44PM  
Was The Smart Money Right About Piling Into Natera Inc (NTRA)?
Insider Monkey -11.04%
09:14AM  
Imagine Holding Natera (NASDAQ:NTRA) Shares While The Price Zoomed 798% Higher
Simply Wall St.
May-06-21 06:50PM  
Natera (NTRA) Reports Q1 Loss, Tops Revenue Estimates
Zacks -8.21%
04:05PM  
Natera Reports First Quarter 2021 Financial Results
PR Newswire
02:45PM  
Natera, Inc. to Host Earnings Call
ACCESSWIRE
May-03-21 09:03AM  
Natera to Present New Colorectal Cancer and Multiple Myeloma Data at the 2021 Annual ASCO Meeting
PR Newswire
Apr-29-21 09:03AM  
Natera Announces First Quarter 2021 Earnings Conference Call
PR Newswire
Apr-28-21 12:33PM  
Earnings Preview: Natera (NTRA) Q1 Earnings Expected to Decline
Zacks
Apr-22-21 11:20AM  
Prospera Transplant Assessment Test: Path Established to Expand Future Coverage to Multiple Organs
PR Newswire
Apr-07-21 09:56AM  
Natera Implements First Wave of Panorama® AI Improvements With Immediate Impact on Patient Experience and COGS
PR Newswire
Apr-03-21 06:12AM  
3 Cancer Diagnostic Monster Stocks on Sale
Motley Fool
Mar-31-21 09:07AM  
Natera and Tesis Labs Announce Strategic Collaboration on Prenatal Genetic Testing
PR Newswire
Mar-24-21 09:03AM  
FDA Grants Two New Breakthrough Device Designations for Natera's Signatera MRD Test
PR Newswire
Mar-23-21 12:21AM  
Is Natera (NTRA) Stock A Buy or Sell?
Insider Monkey
Mar-15-21 12:39PM  
Natera Inc. (NTRA), Among Alger Small Caps Top Contributors
Insider Monkey
Mar-10-21 09:03AM  
Natera and Genentech Initiate Phase III Trial Using Signatera as a Companion Diagnostic for Atezolizumab in Early-Stage Muscle-Invasive Bladder Cancer
PR Newswire
Feb-25-21 04:35PM  
Natera: Q4 Earnings Insights
Benzinga
04:05PM  
Natera Reports Fourth Quarter and Year 2020 Financial Results
PR Newswire
02:30PM  
Natera, Inc. to Host Earnings Call
ACCESSWIRE
Feb-23-21 09:03AM  
Natera to Participate in the Cowen 41st Annual Health Care Conference
PR Newswire
Feb-18-21 09:03AM  
Natera Announces Fourth Quarter and Fiscal 2020 Earnings Conference Call
PR Newswire
Feb-17-21 09:01AM  
Natera and Personalis Partner for Personalized Monitoring in Oncology
Business Wire
Feb-11-21 09:03AM  
Natera to Participate in Upcoming Investor Conferences
PR Newswire
Feb-08-21 07:45AM  
Is Natera (NASDAQ:NTRA) Using Too Much Debt?
Simply Wall St.
Feb-03-21 09:03AM  
Panorama® SMART Study Confirms Market-Leading Performance in Largest Prospective NIPT Trial to Date
PR Newswire
Feb-01-21 09:03AM  
SMART Study Finds 22q11.2 Microdeletion Prevalence Much Higher than Expected
PR Newswire
Jan-20-21 03:04PM  
Natera Files Patent Infringement Suit Against Inivata
PR Newswire
Jan-14-21 10:35AM  
New Data at the 2021 ASTS Winter Symposium to Showcase Benefit of Serial Prospera Testing
PR Newswire
Jan-12-21 09:03AM  
Natera to Present New Colorectal Cancer Data at the 2021 ASCO GI Symposium
PR Newswire
Jan-09-21 08:29AM  
These Were the 5 Best Diagnostics Stocks of 2020
Motley Fool
Jan-05-21 09:03AM  
Natera to Webcast Live Presentation at the 39th Annual J.P. Morgan Healthcare Conference
PR Newswire
Dec-29-20 11:05AM  
Is Natera (NTRA) a Smart Long-term Buy?
Insider Monkey -6.47%
Dec-18-20 09:03AM  
U.S. Patent Office Upholds Validity of Natera's Early Priority Date '592 cfDNA Patent
PR Newswire
Dec-14-20 07:16PM  
Is NTRA A Good Stock To Buy Now?
Insider Monkey
Dec-09-20 09:03AM  
New Signatera Data to be Presented at the 2020 ESMO IO Congress from the Phase III IMvigor010 Trial
PR Newswire
Dec-08-20 09:03AM  
Natera to Present New Immunotherapy Monitoring Data at SABCS 2020
PR Newswire
Dec-03-20 09:03AM  
Second Largest Commercial Insurer Covers Non-Invasive Prenatal Testing for All Pregnancies
PR Newswire
Dec-01-20 10:32AM  
Largest U.S. Health Plan Now Covers Non-Invasive Prenatal Testing (NIPT) for all Pregnancies
PR Newswire
Nov-30-20 09:03AM  
New Publication from I-SPY 2 Trial Highlights Signatera's Ability to Predict Treatment Outcomes in Neoadjuvant Breast Cancer Patients
PR Newswire
Nov-19-20 09:03AM  
Natera Appoints Dr. Monica Bertagnolli to its Board of Directors
PR Newswire
Nov-12-20 09:03AM  
Natera to Present at the Canaccord Genuity Virtual MedTech & Diagnostics Forum
PR Newswire +5.71%
Nov-10-20 09:27AM  
Was The Smart Money Right About Loading Up On Natera Inc (NTRA)?
Insider Monkey
09:03AM  
Natera Presents New Data at the 2020 SITC Annual Meeting Highlighting Applications of Personalized ctDNA Testing in Immunotherapy Treatment Monitoring
PR Newswire
Nov-09-20 06:00AM  
Natera, Inc. (NASDAQ:NTRA) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Simply Wall St.
Nov-05-20 08:10PM  
Natera (NTRA) Reports Q3 Loss, Tops Revenue Estimates
Zacks
04:05PM  
Natera Reports Third Quarter 2020 Financial Results
PR Newswire
02:45PM  
Natera, Inc. to Host Earnings Call
ACCESSWIRE
Oct-30-20 09:03AM  
International Society for Prenatal Diagnosis Recommends cfDNA Screening in Twin Pregnancies
PR Newswire
Oct-29-20 03:52PM  
Battered by the Pandemic, Small-Caps Look Ready to Shine
Barrons.com
01:04PM  
Natera Announces Third Quarter 2020 Earnings Conference Call
PR Newswire
09:03AM  
NIPT for Average Risk Now Covered for 139 Million Commercial Lives
PR Newswire
Oct-28-20 12:32PM  
Natera (NTRA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Zacks -5.63%
Oct-27-20 03:03PM  
Why Exact Sciences $2.15 Billion Deal Has Investors Excited About Cancer-Screening Technology
Barrons.com
Oct-21-20 09:03AM  
Natera to Present New Data at ASN Kidney Week 2020 Showing Clinical Differentiation of the Prospera Test
PR Newswire
Oct-08-20 09:03AM  
Natera's Panorama® NIPT Receives Average Risk Coverage for an Additional 24 Million Lives
PR Newswire
Oct-05-20 09:13AM  
Natera Teams Up with the George Lopez Foundation on the #GLFTrickShot Kidney Disease Awareness Challenge
PR Newswire
09:03AM  
Court Rejects ArcherDX's Motion to Dismiss Natera's Patent Infringement Case
PR Newswire
Oct-02-20 09:03AM  
Natera Announces Prospective Randomized Clinical Trial to Evaluate Palbociclib in Early Stage Breast Cancer Patients Who Test Positive with Signatera
PR Newswire
Sep-28-20 08:50AM  
Natera (NTRA) Surges: Stock Moves 5.8% Higher
Zacks
Sep-24-20 03:49PM  
Medicare Issues Draft Local Coverage Determination for Signatera in Immunotherapy Response Monitoring
PR Newswire
Sep-18-20 09:03AM  
Natera to Present New Gastrointestinal Cancer Data at the ESMO Annual Meeting
PR Newswire
Sep-17-20 09:41AM  
Benzinga's Top Upgrades, Downgrades For September 17, 2020
Benzinga
Sep-14-20 09:03AM  
Natera Launches Initiative to Transform the Management of Cancer Patients in Organ Transplantation
PR Newswire
Sep-11-20 09:03AM  
Natera's Signatera MRD Test Receives a Final Coverage Decision from Noridian in Colorectal Cancer
PR Newswire
12:53AM  
Natera Announces Pricing of Follow-On Offering
PR Newswire
Sep-10-20 02:41PM  
Natera to Present at the Morgan Stanley 18th Annual Global Healthcare Conference
PR Newswire
08:56AM  
Hedge Funds Never Been This Bullish On Natera Inc (NTRA)
Insider Monkey
Sep-09-20 05:07PM  
Natera Launches Proposed Follow-On Offering
PR Newswire
Sep-03-20 10:37AM  
Natera Receives Final Medicare Coverage for its Signatera MRD Test in Stage II-III Colorectal Cancer
PR Newswire
Sep-02-20 06:43PM  
SMART Study Data for Aneuploidy and 22q Unblinded
PR Newswire
Sep-01-20 09:03AM  
Study Shows Clinical Utility of the Prospera Test in Nephrology Practice
PR Newswire
Aug-27-20 09:03AM  
Natera Announces Collaboration with Massachusetts General Hospital for a Prospective Randomized Clinical Trial in Early Stage Breast Cancer
PR Newswire
Aug-26-20 09:03AM  
Natera's Signatera Test Receives CE Mark
PR Newswire
Aug-18-20 09:03AM  
Joint Guideline from ACOG and SMFM Supports use of Non-Invasive Prenatal Testing (NIPT) for all Pregnant Women
PR Newswire
Aug-13-20 12:09PM  
Return On Capital Employed Overview: Natera
Benzinga +5.40%
Aug-11-20 11:17AM  
The Natera (NASDAQ:NTRA) Share Price Has Soared 366%, Delighting Many Shareholders
Simply Wall St.
11:16AM  
Shareholders Are Raving About How The Natera (NASDAQ:NTRA) Share Price Increased 366%
Simply Wall St.
Aug-07-20 09:03AM  
Natera Files Additional Suit Against ArcherDX
PR Newswire
Aug-05-20 06:35PM  
Natera (NTRA) Reports Q2 Loss, Tops Revenue Estimates
Zacks
04:05PM  
Natera Reports Second Quarter 2020 Financial Results
PR Newswire
Aug-04-20 09:41AM  
Healthcare Stock Q2 Earnings Roster for Aug 5: HUM, CRL & More
Zacks
Aug-03-20 11:20AM  
New Publication in Nature Cancer Demonstrates Signatera's Ability to Evaluate Tumor Response to Immunotherapy
PR Newswire
Jul-29-20 12:33PM  
Analysts Estimate Natera (NTRA) to Report a Decline in Earnings: What to Look Out for
Zacks
09:03AM  
Natera Announces Second Quarter 2020 Earnings Conference Call
PR Newswire
Jul-14-20 12:33PM  
Natera Inc (NTRA): Are Hedge Funds Right About This Stock?
Insider Monkey +5.23%
09:03AM  
Natera Recognized as a 'Force for Change' by Leading Women Entrepreneurs (LWE)
PR Newswire
Jun-22-20 09:03AM  
Natera Expands Lab Footprint With State-Of-The-Art Facility in Austin, Texas
PR Newswire
Jun-18-20 09:05AM  
Natera Announces First Patient Enrollments in Both CIRCULATE-Japan and BESPOKE CRC Trials Using Signatera MRD Testing
PR Newswire
Jun-17-20 12:22PM  
Natera Files Patent Suit Against Progenity, Inc.
PR Newswire
Jun-09-20 02:45AM  
Edited Transcript of NTRA earnings conference call or presentation 6-May-20 8:30pm GMT
Thomson Reuters StreetEvents
Jun-08-20 12:52PM  
Edited Transcript of NTRA earnings conference call or presentation 26-Feb-20 9:30pm GMT
Thomson Reuters StreetEvents
Jun-05-20 11:35AM  
Here is What Hedge Funds Think About Natera Inc (NTRA)
Insider Monkey
Jun-02-20 10:00AM  
Moving Average Crossover Alert: Natera
Zacks
Jun-01-20 09:07AM  
Natera Launches Quantification Technique to Enhance Prospera Test Precision; Initiates PEDAL Study for New Insights
PR Newswire
May-26-20 10:08AM  
Natera Announces New Prospera Data at ATC Showcasing Innovation in Cell-Free DNA
PR Newswire
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Brophy Michael BurkesCHIEF FINANCIAL OFFICERJun 10Sale102.611,209124,05095,731Jun 11 06:55 PM
Chapman Steven LeonardCEO AND PRESIDENTJun 10Sale102.611,158118,81778,556Jun 11 06:56 PM
RABINOWITZ DANIELSEC. AND CHIEF LEGAL OFFICERJun 10Sale102.6191193,47348,227Jun 11 06:56 PM
Rabinowitz MatthewEXECUTIVE CHAIRMANJun 10Sale102.6069871,617579,594Jun 11 06:58 PM
Sheena JonathanCO-FOUNDERJun 10Sale102.601,034106,090474,135Jun 11 07:00 PM
Schueren Robert AlanCHIEF OPERATING OFFICERJun 08Sale105.2112,0731,270,17348,827Jun 10 07:29 PM
BOTHA ROELOFDirectorJun 04Option Exercise40.9311,424467,58411,424Jun 08 06:01 PM
Brophy Michael BurkesCHIEF FINANCIAL OFFICERJun 04Sale97.513,489340,20293,919Jun 07 09:04 PM
Chapman Steven LeonardCEO AND PRESIDENTJun 04Sale97.514,709459,16077,418Jun 07 09:05 PM
RABINOWITZ DANIELCHIEF LEGAL OFFICERJun 04Sale97.513,140306,17247,367Jun 07 09:09 PM
Schueren Robert AlanCHIEF OPERATING OFFICERJun 04Sale97.514,395428,54326,252Jun 08 06:00 PM
Brophy Michael BurkesCHIEF FINANCIAL OFFICERMay 18Option Exercise12.4620,807259,240109,465May 20 06:39 PM
Brophy Michael BurkesCHIEF FINANCIAL OFFICERMay 18Sale93.3020,8071,941,26288,658May 20 06:39 PM
BOTHA ROELOFDirectorMay 14Sale93.6067,8876,353,8851,127,160May 18 05:11 PM
Chapman Steven LeonardCEO AND PRESIDENTMay 14Sale93.0513,0071,210,25172,752May 18 06:06 PM
Sheena JonathanCO-FOUNDERMay 10Option Exercise1.1410,00011,410472,878May 12 06:06 PM
Brophy Michael BurkesCHIEF FINANCIAL OFFICERApr 22Sale110.143,213353,87088,658Apr 26 07:01 PM
Rabinowitz MatthewEXECUTIVE CHAIRMANApr 14Sale108.54768,249577,474Apr 14 07:33 PM
Schueren Robert AlanCHIEF OPERATING OFFICERApr 13Option Exercise13.011,28116,66630,160Apr 14 07:34 PM
Brophy Michael BurkesCHIEF FINANCIAL OFFICERApr 13Sale104.2114,6161,523,17091,871Apr 14 07:32 PM
Chapman Steven LeonardCEO AND PRESIDENTApr 13Sale104.2141,6504,340,45185,759Apr 14 07:32 PM
Schueren Robert AlanCHIEF OPERATING OFFICERApr 13Sale104.2122,0932,302,36728,879Apr 14 07:34 PM
Sheena JonathanCO-FOUNDERApr 13Sale104.213,213334,835462,878Apr 14 07:34 PM
Schueren Robert AlanCHIEF OPERATING OFFICERApr 09Sale104.861,912200,5016,982Apr 09 08:58 PM
Chapman Steven LeonardCHIEF EXECUTIVE OFFICERApr 05Sale104.091,558162,17244,479Apr 06 06:06 PM
Brophy Michael BurkesCHIEF FINANCIAL OFFICERMar 29Sale83.964,027338,11569,821Mar 30 06:37 PM
Schueren Robert AlanCHIEF OPERATING OFFICERMar 29Sale83.946,088511,0524,909Mar 30 06:38 PM
Sheena JonathanCO-FOUNDERMar 29Sale83.9558649,194458,941Mar 30 06:38 PM
Chapman Steven LeonardCHIEF EXECUTIVE OFFICERMar 29Sale83.9511,476963,41149,162Mar 29 09:39 PM
Sheena JonathanCO-FOUNDERMar 26Option Exercise1.1410,00011,410457,740Mar 30 06:38 PM
Chapman Steven LeonardCHIEF EXECUTIVE OFFICERMar 25Option Exercise10.509,630101,11939,906Mar 29 09:39 PM
Brophy Michael BurkesCHIEF FINANCIAL OFFICERMar 23Sale101.7243644,35164,682Mar 23 07:32 PM
Chapman Steven LeonardCHIEF EXECUTIVE OFFICERMar 23Sale101.721,683171,19230,276Mar 23 07:33 PM
Rabinowitz MatthewEXECUTIVE CHAIRMANMar 23Sale101.7210110,274577,243Mar 23 07:34 PM
Sheena JonathanCO-FOUNDERMar 23Sale101.7213814,037447,740Mar 23 07:37 PM
Brophy Michael BurkesCHIEF FINANCIAL OFFICERMar 22Sale105.0444847,05864,040Mar 23 07:32 PM
Chapman Steven LeonardCHIEF EXECUTIVE OFFICERMar 22Sale105.0455858,61228,652Mar 23 07:33 PM
Sheena JonathanCO-FOUNDERMar 22Sale105.0433134,768447,423Mar 23 07:37 PM
Brophy Michael BurkesCHIEF FINANCIAL OFFICERMar 16Sale110.232,234246,25463,370Mar 18 06:01 PM
Cozzens Todd CDirectorMar 11Option Exercise1.3920,00027,71027,278Mar 11 07:23 PM
Cozzens Todd CDirectorMar 11Sale103.6920,0002,073,8727,278Mar 11 07:23 PM
Schueren Robert AlanCHIEF OPERATING OFFICERMar 11Sale102.556,173633,0160Mar 11 07:26 PM
Chapman Steven LeonardCHIEF EXECUTIVE OFFICERMar 11Sale99.6317,9221,785,53328,092Mar 12 06:32 PM
Brophy Michael BurkesCHIEF FINANCIAL OFFICERMar 10Sale97.315,954579,39465,604Mar 11 07:12 PM
Rabinowitz MatthewEXECUTIVE CHAIRMANMar 10Sale97.3176674,537576,943Mar 11 07:16 PM
Sheena JonathanCO-FOUNDERMar 10Sale97.3270368,416446,636Mar 11 07:19 PM
Schueren Robert AlanCHIEF OPERATING OFFICERMar 10Sale97.336,327615,7976,173Mar 11 07:26 PM
Chapman Steven LeonardCHIEF EXECUTIVE OFFICERMar 10Sale97.319,072882,79646,014Mar 10 07:07 PM
Cozzens Todd CDirectorMar 09Option Exercise1.3929,47540,83836,753Mar 11 07:23 PM
Chapman Steven LeonardCHIEF EXECUTIVE OFFICERMar 09Option Exercise15.6922,327350,26177,413Mar 10 07:07 PM
Cozzens Todd CDirectorMar 09Sale100.3529,4752,957,8757,278Mar 11 07:23 PM
Chapman Steven LeonardCHIEF EXECUTIVE OFFICERMar 09Sale99.3022,3272,217,05855,086Mar 10 07:07 PM
Chapman Steven LeonardCHIEF EXECUTIVE OFFICERMar 08Option Exercise11.4720,000229,32957,164Mar 10 07:07 PM
Chapman Steven LeonardCHIEF EXECUTIVE OFFICERMar 08Sale96.7020,0001,933,92537,164Mar 10 07:07 PM
Chapman Steven LeonardCHIEF EXECUTIVE OFFICERMar 03Option Exercise10.411,39014,47038,554Mar 05 06:43 PM
Chapman Steven LeonardCHIEF EXECUTIVE OFFICERMar 03Sale115.001,390159,85037,164Mar 05 06:43 PM
Chapman Rowan EDirectorMar 01Option Exercise32.158,000257,2008,000Mar 03 06:58 PM
Chapman Rowan EDirectorMar 01Sale122.236,000733,4082,000Mar 03 06:58 PM
Brophy Michael BurkesCHIEF FINANCIAL OFFICERFeb 25Sale106.731,899202,68356,037Feb 25 08:00 PM
Sheena JonathanCO-FOUNDERFeb 25Sale106.691,038110,746445,047Feb 25 08:02 PM
Sheena JonathanCO-FOUNDERFeb 24Option Exercise1.1410,00011,410446,085Feb 25 08:02 PM
Schueren Robert AlanCHIEF OPERATING OFFICERFeb 12Option Exercise13.011,61821,05050,437Feb 16 08:42 PM
Chapman Steven LeonardCHIEF EXECUTIVE OFFICERFeb 01Option Exercise13.733,84052,72841,004Feb 03 07:10 PM
Rabinowitz MatthewEXECUTIVE CHAIRMANFeb 01Sale107.4021222,769574,891Feb 02 06:54 PM
Chapman Steven LeonardCHIEF EXECUTIVE OFFICERFeb 01Sale108.123,840415,17937,164Feb 03 07:10 PM
Sheena JonathanCO-FOUNDERJan 22Option Exercise1.1440,00045,640432,860Jan 26 07:45 PM
Sheena JonathanCO-FOUNDERJan 19Option Exercise1.1450,00057,050392,860Jan 21 06:27 PM
Chapman Steven LeonardCHIEF EXECUTIVE OFFICERJan 13Option Exercise16.238,155132,39545,319Jan 15 06:27 PM
Sheena JonathanCO-FOUNDERJan 13Option Exercise1.1450,00057,050342,860Jan 15 06:32 PM
Chapman Steven LeonardCHIEF EXECUTIVE OFFICERJan 13Sale115.008,155937,82537,164Jan 15 06:27 PM
Schueren Robert AlanCHIEF OPERATING OFFICERJan 08Sale109.322,066225,85551,274Jan 11 06:28 PM
Chapman Steven LeonardCHIEF EXECUTIVE OFFICERJan 04Option Exercise14.083,33246,92042,054Jan 06 06:02 PM
Chapman Steven LeonardCHIEF EXECUTIVE OFFICERJan 04Sale99.494,890486,50637,164Jan 06 06:02 PM
Brophy Michael BurkesCHIEF FINANCIAL OFFICERDec 24Option Exercise12.9860,755788,366128,497Dec 28 06:01 PM
Brophy Michael BurkesCHIEF FINANCIAL OFFICERDec 24Sale110.4677,9148,606,60950,583Dec 28 06:01 PM
Brophy Michael BurkesCHIEF FINANCIAL OFFICERDec 23Sale110.8342747,32467,742Dec 28 06:01 PM
Chapman Steven LeonardCHIEF EXECUTIVE OFFICERDec 23Sale110.831,649182,75935,597Dec 28 05:54 PM
Schueren Robert AlanCHIEF OPERATING OFFICERDec 22Sale105.475,999632,74549,356Dec 22 07:44 PM
Chapman Steven LeonardCHIEF EXECUTIVE OFFICERDec 22Sale105.475,056533,28233,940Dec 22 07:41 PM
Brophy Michael BurkesCHIEF FINANCIAL OFFICERDec 22Sale105.475,208549,31467,092Dec 22 07:31 PM
Schueren Robert AlanCHIEF OPERATING OFFICERDec 14Option Exercise13.0110,000130,10062,855Dec 16 07:18 PM
Schueren Robert AlanCHIEF OPERATING OFFICERDec 14Sale100.6720,0002,013,49542,855Dec 16 07:18 PM
Chapman Steven LeonardCHIEF EXECUTIVE OFFICERDec 10Sale92.601,163107,69128,504Dec 11 06:43 PM
Sheena JonathanCO-FOUNDERDec 10Sale92.601,03896,116291,288Dec 11 06:41 PM
Rabinowitz MatthewEXECUTIVE CHAIRMANDec 10Sale92.5999692,218574,396Dec 11 06:31 PM
Brophy Michael BurkesCHIEF FINANCIAL OFFICERDec 10Sale92.591,214112,40358,683Dec 11 06:26 PM
Marcus Gail BoxerDirectorNov 20Option Exercise12.7819,169245,03019,169Nov 24 07:43 PM
BOTHA ROELOFDirectorNov 20Option Exercise17.1192,9831,590,63592,983Nov 24 07:39 PM
Marcus Gail BoxerDirectorNov 20Sale85.2919,1691,635,0050Nov 24 07:43 PM
Chapman Rowan EDirectorNov 12Option Exercise32.153,00096,4503,000Nov 16 07:06 PM
Chapman Rowan EDirectorNov 12Sale83.473,000250,4250Nov 16 07:06 PM
Chapman Steven LeonardChief Executive OfficerNov 11Option Exercise21.9261,6491,351,39989,020Nov 12 09:33 PM
Chapman Steven LeonardChief Executive OfficerNov 11Sale77.9894,3797,359,79727,371Nov 12 09:33 PM
Rabinowitz MatthewExecutive ChairmanNov 11Sale77.8670,0005,450,53740,000Nov 12 09:31 PM
Chapman Steven LeonardChief Executive OfficerNov 10Option Exercise9.8935,621352,18262,992Nov 12 09:33 PM
Chapman Steven LeonardChief Executive OfficerNov 10Sale77.6735,6212,766,55527,371Nov 12 09:33 PM
Rabinowitz MatthewExecutive ChairmanNov 10Sale77.3690,0006,962,222110,000Nov 12 09:31 PM
Rabinowitz MatthewExecutive ChairmanNov 09Sale81.3190,0007,317,987200,000Nov 12 09:31 PM
Chapman Steven LeonardChief Executive OfficerNov 04Option Exercise14.0151,822725,95268,410Nov 06 06:28 PM
Chapman Steven LeonardChief Executive OfficerNov 04Sale75.0061,3514,601,32527,371Nov 06 06:28 PM
open in yahoo | open in reuters | open in marketwatch | open in google
affiliate • advertise • contact • privacy • help
Do not sell my personal information
Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2021 FINVIZ.com. All Rights Reserved.